Gethin W Hodges1, Casper N Bang2, Jesper Eugen-Olsen3, Michael H Olsen4, Kurt Boman5, Simon Ray6, Christa Gohlke-Bärwolf7, Y Antero Kesäniemi8, Jørgen L Jeppesen9, Kristian Wachtell10. 1. Department of Medicine Glostrup, Amager and Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark. Electronic address: gethin.william.hodges@regionh.dk. 2. Department of Cardiology, Roskilde University Hospital, Roskilde, Denmark. 3. Clinical Research Centre, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark. 4. Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, Odense, Denmark; Department of Internal Medicine, Holbæk Hospital, Holbæk, Denmark; Cardiovascular Centre of Excellence (CAVAC), University of Southern Denmark, Odense, Denmark. 5. Research Unit, Skellefteå, Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. 6. Department of Cardiology, University Hospitals of South Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom. 7. Heart Center Bad Krozingen, Bad Krozingen, Germany. 8. Research Institute of Internal Medicine, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland. 9. Department of Medicine Glostrup, Amager and Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark. 10. Department of Cardiology, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND:Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with subclinical cardiovascular damage and cardiovascular events. Whether suPAR is of prognostic value in asymptomatic patients with aortic stenosis (AS) remains unknown. METHODS:Plasma suPAR levels were measured in 1503 patients with a mean age of 68 years who were recruited in theSimvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Cox regression analysis was performed to evaluate associations between suPAR and the composite end points of ischemic cardiovascular events (ICEs), aortic valve events (AVEs), cardiovascular and all-cause mortality after adjusting for traditional cardiovascular risk factors, and allocation to treatment. RESULTS: The multivariate adjusted hazard ratio (HR) (95% confidence interval [CI]) per unit log2 ng/mL increase in suPAR was HR, 1.5; 95% CI, 1.2-1.9; P = 0.002 for ICEs; HR, 1.2; 95% CI, 0.9-1.5; P = 0.071) for AVEs; HR, 2.0; 95% CI, 1.2-3.3; P = 0.007) for cardiovascular mortality, and HR, 2.0; 95% CI, 1.4-2.9; P < 0.001 for all-cause mortality. CONCLUSIONS: In patients with mild-moderate AS, suPAR is independently associated with the incidence of ICEs, cardiovascular mortality, and all-cause mortality. Copyright Â
RCT Entities:
BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) is an inflammatory marker associated with subclinical cardiovascular damage and cardiovascular events. Whether suPAR is of prognostic value in asymptomatic patients with aortic stenosis (AS) remains unknown. METHODS: Plasma suPAR levels were measured in 1503 patients with a mean age of 68 years who were recruited in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Cox regression analysis was performed to evaluate associations between suPAR and the composite end points of ischemic cardiovascular events (ICEs), aortic valve events (AVEs), cardiovascular and all-cause mortality after adjusting for traditional cardiovascular risk factors, and allocation to treatment. RESULTS: The multivariate adjusted hazard ratio (HR) (95% confidence interval [CI]) per unit log2 ng/mL increase in suPAR was HR, 1.5; 95% CI, 1.2-1.9; P = 0.002 for ICEs; HR, 1.2; 95% CI, 0.9-1.5; P = 0.071) for AVEs; HR, 2.0; 95% CI, 1.2-3.3; P = 0.007) for cardiovascular mortality, and HR, 2.0; 95% CI, 1.4-2.9; P < 0.001 for all-cause mortality. CONCLUSIONS: In patients with mild-moderate AS, suPAR is independently associated with the incidence of ICEs, cardiovascular mortality, and all-cause mortality. Copyright Â
Authors: Dimitrios Velissaris; Nicholas Zareifopoulos; Ioanna Koniari; Vasilios Karamouzos; Dimitris Bousis; Andreas Gerakaris; Christina Platanaki; Nicholas Kounis Journal: J Clin Med Res Date: 2021-03-19
Authors: Gethin W Hodges; Casper N Bang; Jesper Eugen-Olsen; Michael H Olsen; Kurt Boman; Simon Ray; Antero Y Kesäniemi; Jørgen L Jeppesen; Kristian Wachtell Journal: Open Heart Date: 2018-01-13
Authors: Laura Bäz; Gudrun Dannberg; Katja Grün; Julian Westphal; Sven Möbius-Winkler; Christian Jung; Alexander Pfeil; P Christian Schulze; Marcus Franz Journal: Int J Mol Sci Date: 2020-06-11 Impact factor: 5.923